Fortrea agreed to acquire Worldwide Clinical Trials’ early-phase services business for $45 million, adding three Texas facilities and expanding its clinical pharmacology and bioanalytical footprint. The deal includes a 200-bed clinical pharmacology unit and bioanalytical labs, plus a biospecimen storage site. Fortrea said the acquisition is designed to reverse revenue decline and better meet customer demand for cohesive early development capabilities, combining small- and large-molecule bioanalytical capacity. Worldwide will continue providing early-phase services through its wider business, while using proceeds to invest in late-stage services and technology. CRO consolidation at this scale can alter sponsor expectations on timelines, recruitment logistics, and domiciling for early-stage trials. For biotech teams planning IND-enabling work through Phase 1, expanded pharmacology capacity may reduce bottlenecks tied to bioanalytical turnaround and volunteer access in metro regions.